QURENasdaqPharmaceutical PreparationsFiscal year ends December 31
uniQure N.V.
Financials through Q1 FY2026, quarter ended Mar 31, 2026Last filing: 10-Q on Jul 29, 2026
$22.20+0.42 (+1.93%)
Close on Oct 19, 2026
- Market cap
- $1.39B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$35.80 (−61.72%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
uniQure N.V. saw revenue fall 10.4% to $18.09M over the twelve months to Mar 31, 2026. Free cash flow was -$172.56M.
Revenue
$18.09M
-10.4% vs. a year earlier
Operating income
-$191.74M
TTM Q1 2026
Free cash flow
-$172.56M
TTM Q1 2026
EPS, diluted
-$3.51
TTM Q1 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Mar 31, 2026
Valuation
- Market cap
- $1.39B
- P/E ratio
- –
- Price to sales
- 76.99
- Price to book
- 9.33
- Dividend yield
- –
- Free cash flow yield
- -12.39%
Fundamentals
- Revenue
- $18.09M
- Net income
- -$208.87M
- EPS, diluted
- -$3.51
- Free cash flow
- -$172.56M
- Book value per share
- $2.38
- Diluted shares
- 63M
Thirteen years at a glance
Fiscal years 2013 to 2025 and trailing twelve months, USD
Revenue
$18.09M-10.4% YoY
Gross profit
$16.39M-13.2% YoY
Operating income
-$191.74M
Net income
-$208.87M
EPS, diluted
-$3.51
Free cash flow
-$172.56M
Reported periodTrailing twelve months